Literature DB >> 19159406

Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.

Søren Fanoe1, Gorm Boje Jensen, Per Sjøgren, Mads P G Korsgaard, Morten Grunnet.   

Abstract

WHAT IS ALREADY KNOWN: During recent years some opioids have been associated with prolonged QT and torsade de pointes (TdP). In vitro testing has shown that most opioids can block the cardiac potassium channels. This indicates that QT prolongation and TdP could be a more general problem associated with the use of these drugs. WHAT THIS PAPER ADDS: This study is the first to show that oxycodone dose is associated with QT prolongation and in vitro blockade of hERG channels expressed in HEK293. Neither morphine nor tramadol doses are associated with the QT interval length. AIMS: During recent years some opioids have been associated with prolonged QT interval and torsade de pointes (TdP). In vitro patch clamp testing has shown that most opioids can block human ether-a-go-go related gene (hERG) channels that are known to underlie cardiac repolarizing I(Kr) current. This indicates that QT prolongation and TdP could be a more general problem associated with the use of these drugs. The aims of this study were to evaluate the association between different opioids and the QTc among patients and measure hERG activity under influence by opioids in vitro.
METHODS: One hundred chronic nonmalignant pain patients treated with methadone, oxycodone, morphine or tramadol were recruited in a cross-sectional study. The QTc was estimated from a 12-lead ECG. To examine hERG activity in the presence of oxycodone, electrophysiological testing was conducted using Xenopus laevis oocytes and HEK293 cells expressing hERG channels.
RESULTS: There were no differences in gender distribution or age between the treatment groups. The known association between methadone dose and QTc was confirmed (R(2) = 0.09; P = 0.02). Higher oxycodone dose was also associated with longer QTc (R(2) = 0.21; P = 0.02). A 100 mg higher oxycodone dose was associated with a 10 ms(1/2) (95% CI 2-19) longer QTc. Neither morphine nor tramadol dose was associated with the QTc. Electrophysiological testing revealed low-affinity inhibition of the potassium current through hERG channels expressed in HEK293 cells (IC(50) = 171 microM oxycodone).
CONCLUSIONS: Among patients treated with methadone or oxycodone, higher doses were associated with longer QTc. Oxycodone is capable of inhibiting hERG channels in vitro.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19159406      PMCID: PMC2670374          DOI: 10.1111/j.1365-2125.2008.03327.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  28 in total

Review 1.  Equianalgesic dose ratios for opioids. a critical review and proposals for long-term dosing.

Authors:  J Pereira; P Lawlor; A Vigano; M Dorgan; E Bruera
Journal:  J Pain Symptom Manage       Date:  2001-08       Impact factor: 3.612

2.  The impact of methadone induction on cardiac conduction in opiate users.

Authors:  Bridget A Martell; Julia H Arnsten; Beevash Ray; Marc N Gourevitch
Journal:  Ann Intern Med       Date:  2003-07-15       Impact factor: 25.391

3.  Dual-function vector for protein expression in both mammalian cells and Xenopus laevis oocytes.

Authors:  T Jespersen; M Grunnet; K Angelo; D A Klaerke; S P Olesen
Journal:  Biotechniques       Date:  2002-03       Impact factor: 1.993

4.  Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents.

Authors:  Alexander N Katchman; Kelly A McGroary; Michael J Kilborn; Craig A Kornick; Paolo L Manfredi; Raymond L Woosley; Steven N Ebert
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

Review 5.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

Authors:  W S Redfern; L Carlsson; A S Davis; W G Lynch; I MacKenzie; S Palethorpe; P K S Siegl; I Strang; A T Sullivan; R Wallis; A J Camm; T G Hammond
Journal:  Cardiovasc Res       Date:  2003-04-01       Impact factor: 10.787

Review 6.  When "enough" is not enough: new perspectives on optimal methadone maintenance dose.

Authors:  S B Leavitt; M Shinderman; S Maxwell; C B Eap; P Paris
Journal:  Mt Sinai J Med       Date:  2000 Oct-Nov

7.  Torsade de pointes associated with very-high-dose methadone.

Authors:  Mori J Krantz; Laurent Lewkowiez; Helen Hays; Mary Ann Woodroffe; Alastair D Robertson; Philip S Mehler
Journal:  Ann Intern Med       Date:  2002-09-17       Impact factor: 25.391

8.  Changes in methadone treatment practices: results from a national panel study, 1988-2000.

Authors:  Thomas D'Aunno; Harold A Pollack
Journal:  JAMA       Date:  2002-08-21       Impact factor: 56.272

9.  QTc interval prolongation associated with intravenous methadone.

Authors:  Craig A Kornick; Michael J Kilborn; Juan Santiago-Palma; Glenn Schulman; Howard T Thaler; Deborah L Keefe; Alexander N Katchman; John C Pezzullo; Steven N Ebert; Raymond L Woosley; Richard Payne; Paolo L Manfredi
Journal:  Pain       Date:  2003-10       Impact factor: 6.961

10.  Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.

Authors:  Søren Fanoe; Christian Hvidt; Peter Ege; Gorm Boje Jensen
Journal:  Heart       Date:  2007-03-07       Impact factor: 5.994

View more
  25 in total

1.  Nonclinical safety assessment of PF614: A novel TAAP prodrug of oxycodone for chronic pain indication.

Authors:  P S Joshi; N Sanakkayala; L Kirkpatrick; P S Terse
Journal:  Regul Toxicol Pharmacol       Date:  2019-07-27       Impact factor: 3.271

2.  [ECG changes in patients with chronic non-cancer pain: a prospective observational study].

Authors:  V Peuckmann-Post; R Eickhoff; M Becker; D von der Laage
Journal:  Schmerz       Date:  2012-08       Impact factor: 1.107

3.  Effect of lofexidine on cardiac repolarization during treatment of opioid withdrawal.

Authors:  Börje Darpö; Mark Pirner; James Longstreth; Georg Ferber
Journal:  Drug Alcohol Depend       Date:  2019-09-27       Impact factor: 4.492

4.  A research agenda for gender and substance use disorders in the emergency department.

Authors:  Esther K Choo; Gillian Beauchamp; Francesca L Beaudoin; Edward Bernstein; Judith Bernstein; Steven L Bernstein; Kerryann B Broderick; Robert D Cannon; Gail D'Onofrio; Marna R Greenberg; Kathryn Hawk; Rashelle B Hayes; Gabrielle A Jacquet; Melanie J Lippmann; Karin V Rhodes; Susan H Watts; Edwin D Boudreaux
Journal:  Acad Emerg Med       Date:  2014-12-01       Impact factor: 3.451

5.  A dual mechanism for I(Ks) current reduction by the pathogenic mutation KCNQ1-S277L.

Authors:  Jerri Chen; Michael Weber; Sung Yon Um; Christine A Walsh; Yingying Tang; Thomas V McDonald
Journal:  Pacing Clin Electrophysiol       Date:  2011-09-02       Impact factor: 1.976

6.  The opioid oxycodone use-dependently inhibits the cardiac sodium channel NaV 1.5.

Authors:  Jannis E Meents; Krisztina Juhasz; Sonja Stölzle-Feix; Vera Peuckmann-Post; Roman Rolke; Angelika Lampert
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

7.  Racial susceptibility for QT prolongation in acute drug overdoses.

Authors:  Alex F Manini; Barry Stimmel; David Vlahov
Journal:  J Electrocardiol       Date:  2013-12-04       Impact factor: 1.438

Review 8.  Opioids and Cardiac Arrhythmia: A Literature Review.

Authors:  Mina Behzadi; Siyavash Joukar; Ahmad Beik
Journal:  Med Princ Pract       Date:  2018-08-02       Impact factor: 1.927

Review 9.  Medical and psychological risks and consequences of long-term opioid therapy in women.

Authors:  Beth D Darnall; Brett R Stacey; Roger Chou
Journal:  Pain Med       Date:  2012-08-20       Impact factor: 3.750

10.  Prescription Opioid Use and Risk of Coronary Heart Disease, Stroke, and Cardiovascular Death Among Adults from a Prospective Cohort (REGARDS Study).

Authors:  Yulia Khodneva; Paul Muntner; Stefan Kertesz; Brett Kissela; Monika M Safford
Journal:  Pain Med       Date:  2016-02-08       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.